N/A
N=185
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
Hepatitis C, Chronic · Hepatitis C
Bottom Line
View on ClinicalTrials.gov: NCT00704717 ↗Enrolled (actual)
185
Serious AEs
0.0%
Results posted
Jun 2009
Primary outcome: Primary: Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey. — 6.16 Units on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- PegIntron (peginterferon alfa-2b; SCH 54031) pen (Biological); Rebetol (ribavirin; SCH 18908) (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Dec 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey. |
6.16 | — |
Summary
The objective of this study is to evaluate patient satisfaction in hepatitis C patients receiving PegIntron pen plus Rebetol. The rationale is that the effectiveness of treatment is correlated with adherence to the prescribed regimen which, in turn, is affected by the ease of use and accuracy of treatment administration. Since the PegIntron pen is a novel device, the results of this study will be used to improve the training of patients and healthcare providers in PegIntron pen use.
Eligibility Criteria
Inclusion Criteria
- Patients with hepatitis C under treatment with PegIntron Pen and Rebetol in Romania.
Exclusion Criteria
- Not applicable
Data sourced from ClinicalTrials.gov (NCT00704717). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.